Viridian Therapeutics Inc
1S1
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Contact
221 Crescent Street
Suite 103A
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
252
Stocks News & Analysis
stocks
Undervalued REIT offers attractive yield post earnings
Resilient income, attractive yield for Aussie REIT.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.40 | 30.80 | 0.33% |
| CAC 40 | 8,579.60 | 57.19 | -0.66% |
| DAX 40 | 26,338.61 | 101.70 | -0.38% |
| Dow JONES (US) | 53,459.78 | 272.63 | -0.51% |
| FTSE 100 | 10,720.30 | 29.81 | -0.28% |
| HKSE | 25,330.61 | 122.62 | -0.48% |
| NASDAQ | 26,644.91 | 84.25 | -0.32% |
| Nikkei 225 | 68,396.09 | 824.16 | -1.19% |
| NZX 50 Index | 13,744.79 | 22.81 | 0.17% |
| S&P 500 | 7,745.06 | 40.70 | -0.52% |
| S&P/ASX 200 | 9,090.70 | 25.90 | 0.29% |
| SSE Composite Index | 3,982.04 | 0.61 | -0.02% |